Atlas Trials

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Clinical trial NCT01661179 · COMPLETED

Trial details

NCT number
NCT01661179
Sponsor
Genzyme, a Sanofi Company
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Start date
2012-11-01
Primary completion
2013-12-01
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.